TRANSLATIONAL SCIENTIFIC ADVANCES
V. Craig Jordan, OBE, PhD, DSc
Professor, Breast Medical Oncology, and Professor, Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center
    V. Craig Jordan, OBE, PhD, DSc, is recognized for the discovery of the breast cancer prevention properties of tamoxifen, the original selective estrogen receptor modulator (SERM).
    • Dr Jordan’s research led to the discovery that raloxifene prevents both osteoporosis and breast cancer. This and tamoxifen are among 5 SERMs approved by the FDA for a variety of indications, and all 5 drugs (including toremifene, bazedoxifene, and ospemiphene) are connected to basic research in his laboratory.
    • He devised the translational research strategy of targeting estrogen receptor–positive breast cancer for long-term adjuvant tamoxifen therapy and is credited with the discovery of the scientific principles for adjuvant therapy with antihormones. His work related to SERMS has branched out into the prevention of multiple diseases in women.
    • He discovered the tissue-specific pharmacology of tamoxifen that blocks estrogen-stimulated breast cancer growth but simultaneously promotes endometrial cancer growth. Correspondence in the Lancet warned the international clinical community that there was a link between tamoxifen treatment and endometrial cancer.
    • Dr Jordan is the Dallas/Ft Worth Living Legend Professor of Cancer Research at The University of Texas MD Anderson Cancer Center.
Program Information:
Nominate
Sponsor
News
Previous Inductees:
2013 | 2014
2015 | 2016
2017 | 2018
Connect: